

JOHNSON BRENT  
Form 4  
March 07, 2019

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
JOHNSON BRENT

2. Issuer Name and Ticker or Trading Symbol  
IRADIMED CORP [IRMD]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
03/05/2019

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
\_\_\_\_ Officer (give title below) \_\_\_\_\_ Other (specify below)  
Exec. VP of WW Sales and Mktg

C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR.

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

WINTER SPRINGS, FL 32708

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |   |
| Common Stock                    | 03/05/2019                           |  | A                              | 1,860   | A \$ 0.93   | 3,228  | D   |
| Common Stock                    | 03/05/2019                           |  | S                              | 1,860   | D \$ 25.4261  | 1,368  | D   |
| Common Stock                    | 03/06/2019                           |  | A                              | 9,672   | A \$ 0.93   | 11,040   | D   |
| Common Stock                    | 03/06/2019                           |  | S                              | 9,672   | D \$ 24.5834  | 1,368  | D   |

Edgar Filing: JOHNSON BRENT - Form 4

|              |            |  |   |       |   |                             |       |   |
|--------------|------------|--|---|-------|---|-----------------------------|-------|---|
| Common Stock | 03/07/2019 |  | A | 7,614 | A | \$ 0.93                     | 8,962 | D |
| Common Stock | 03/07/2019 |  | S | 7,614 | D | \$<br>24.5223<br><u>(3)</u> | 1,368 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Stock Option (Right to Buy)                | \$ 0.93  | 03/05/2019                           |  | M                              | 1,860   | <u>(4)</u> 12/27/2021                                    | Common Stock  | 1,860                         |
| Stock Option (Right to Buy)                | \$ 0.93  | 03/06/2019                           |  | M                              | 9,672   | <u>(5)</u> 12/27/2021                                    | Common Stock  | 9,672                         |
| Stock Option (Right to Buy)                | \$ 0.93  | 03/07/2019                           |  | M                              | 7,614   | <u>(6)</u> 12/27/2021                                    | Common Stock  | 7,614                         |

## Reporting Owners

| Reporting Owner Name / Address            | Relationships |           |                               |       |
|---|---------------|-----------|-------------------------------|-------|
|   | Director      | 10% Owner | Officer                       | Other |
| JOHNSON BRENT<br>C/O IRADIMED CORPORATION |               |           | Exec. VP of WW Sales and Mktg |       |

1025 WILLA SPRINGS DR.  
WINTER SPRINGS, FL 32708

## Signatures

/s/ Brent

Johnson

03/07/2019

          Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - (1) This transaction was executed in multiple trades at prices ranging from \$25.3 to \$25.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  - (2) This transaction was executed in multiple trades at prices ranging from \$24.5 to \$24.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  - (3) This transaction was executed in multiple trades at prices ranging from \$24.5 to \$24.6. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  - (4) This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date.
  - (5) This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date.
  - (6) This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.